ALAM KHAN: Open Payments
NPI 1316946288 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$685 in 27 payments from 12 companies in 2025. Trend: 2023 $1,515 · 2024 $1,277 · 2025 $685
Food & beverage: $574Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $177 |
| PFIZER INC. | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Amgen Inc. | 3 | $69 |
| Novartis Pharmaceuticals Corporation | 2 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $61 |
| Lilly USA, LLC | 1 | $34 |
| ABBVIE INC. | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 1 | $28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26 |
Products named: REXULTI, ELIQUIS, AUSTEDO XR, LEQVIO, CAPLYTA, KRYSTEXXA, MOUNJARO, VRAYLAR.
Industry payments across IL — which companies pay providers there.
